Related Experiment Video
Updated: Jul 15, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Alcohol Consumption and Antihypertensive Treatment Effect in Male Patients With Hypertension
Xiao-Fei Ye1, Wen-Yuan-Yue Wang1, Xin-Yu Wang1
1Department of Epidemiology and Statistics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Insights
Alcohol drinkers with hypertension required higher antihypertensive medication doses for blood pressure control. At 12 weeks, drinkers needed more medication than non-drinkers to achieve similar hypertension control.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Alcohol consumption is a known risk factor for hypertension.
- This study examined antihypertensive medication use and blood pressure control in male hypertensive alcohol drinkers versus non-drinkers.
Purpose of the Study:
- To investigate the impact of alcohol consumption on the efficacy of antihypertensive medications.
- To compare blood pressure control rates and medication dosage requirements between alcohol drinkers and non-drinkers with hypertension.
Main Methods:
- A 12-week therapeutic study involving male patients with hypertension (systolic/diastolic blood pressure 160-199/100-119 mm Hg).
- Participants were treated with irbesartan/hydrochlorothiazide, with potential dose titration for blood pressure control (<140/90 mm Hg or <130/80 mm Hg for diabetics).
- Alcohol consumption was categorized into drinkers and non-drinkers.
Main Results:
- Baseline blood pressure and characteristics were similar between 68 alcohol drinkers and 168 non-drinkers, except for higher smoking rates in drinkers.
- At 12 weeks, a significantly higher proportion of alcohol drinkers required higher antihypertensive drug dosages compared to non-drinkers (54.7% vs. 36.6%, P=0.01).
- Hypertension control rates were similar at 12 weeks (51.5% vs. 54.8%), despite increased medication dosage in drinkers.
Conclusions:
- Alcohol drinkers with hypertension necessitate higher dosages of antihypertensive medications to achieve comparable blood pressure control versus non-drinkers.
- The findings highlight potential differences in drug response or adherence related to alcohol consumption in hypertensive patients.
Background:
Alcohol consumption is a proven risk factor of hypertension. In the present analysis, we investigated the use of antihypertensive medications and blood pressure control in male alcohol drinkers and non-drinkers with hypertension (systolic/diastolic blood pressure 160-199/100-119 mm Hg).
Methods:
The study participants were patients enrolled in a 12-week therapeutic study and treated with the irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with the possible up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks of follow-up, respectively, for blood pressure control of <140/90 mm Hg or <130/80 mm Hg in patients with diabetes mellitus. Alcohol consumption was classified as non-drinkers and drinkers.
Results:
The 68 alcohol drinkers and 168 non-drinkers had similar systolic/diastolic blood pressure at baseline (160.8 ± 12.1/99.8 ± 8.6 vs. 161.8 ± 11.0/99.2 ± 8.6, P ≥ 0.55) and other characteristics except for current smoking (80.9% vs. 47.6%, P < 0.0001). In patients who completed the 12-week follow-up (n = 215), the use of higher dosages of antihypertensive drugs was similar at 4 weeks of follow-up in drinkers and non-drinkers (10.6% vs. 12.4%, P = 0.70), but increased to a significantly higher proportion in drinkers than non-drinkers at 12 weeks of follow-up (54.7% vs. 36.6%, P = 0.01). The control rate of hypertension tended to be lower in alcohol drinkers, compared with non-drinkers, at 4 weeks of follow-up (45.6% vs. 58.9%, P = 0.06), but became similar at 12 weeks of follow-up (51.5% vs. 54.8%, P = 0.65).
Conclusion:
Alcohol drinkers compared with non-drinkers required a higher dosage of antihypertensive drug treatment to achieve similar blood pressure control.
Clinical Trial Registry Number:
NCT00670566 at www.clinicaltrials.gov.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Antihypertensive Drugs: Action of Diuretics
Hypertension and Regulation of Blood Pressure
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

